NL2003138A1 - Composition for preventing and treating fatty liver. - Google Patents

Composition for preventing and treating fatty liver.

Info

Publication number
NL2003138A1
NL2003138A1 NL2003138A NL2003138A NL2003138A1 NL 2003138 A1 NL2003138 A1 NL 2003138A1 NL 2003138 A NL2003138 A NL 2003138A NL 2003138 A NL2003138 A NL 2003138A NL 2003138 A1 NL2003138 A1 NL 2003138A1
Authority
NL
Netherlands
Prior art keywords
preventing
composition
fatty liver
treating fatty
treating
Prior art date
Application number
NL2003138A
Other languages
English (en)
Other versions
NL2003138C2 (en
Inventor
Frank Chiahung Mao
Wen-Ying Chen
Original Assignee
Nat Univ Chung Hsing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Chung Hsing filed Critical Nat Univ Chung Hsing
Publication of NL2003138A1 publication Critical patent/NL2003138A1/nl
Priority to NL2006318A priority Critical patent/NL2006318C2/en
Application granted granted Critical
Publication of NL2003138C2 publication Critical patent/NL2003138C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL2003138A 2008-07-07 2009-07-06 Composition for preventing and treating fatty liver. NL2003138C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL2006318A NL2006318C2 (en) 2008-07-07 2011-03-01 Composition for use in reducing oxidative stress in liver.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TW97125541 2008-07-07
TW097125541A TW201002332A (en) 2008-07-07 2008-07-07 Composition for preventing and controlling fatty liver disease

Publications (2)

Publication Number Publication Date
NL2003138A1 true NL2003138A1 (nl) 2010-01-11
NL2003138C2 NL2003138C2 (en) 2011-03-07

Family

ID=41464572

Family Applications (2)

Application Number Title Priority Date Filing Date
NL2003138A NL2003138C2 (en) 2008-07-07 2009-07-06 Composition for preventing and treating fatty liver.
NL2006318A NL2006318C2 (en) 2008-07-07 2011-03-01 Composition for use in reducing oxidative stress in liver.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL2006318A NL2006318C2 (en) 2008-07-07 2011-03-01 Composition for use in reducing oxidative stress in liver.

Country Status (5)

Country Link
US (2) US20100003347A1 (nl)
MX (1) MX2009007319A (nl)
MY (1) MY150701A (nl)
NL (2) NL2003138C2 (nl)
TW (1) TW201002332A (nl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2841379T3 (es) * 2007-03-13 2021-07-08 Jds Therapeutics Llc Procedimientos y composiciones para la liberación sostenida de cromo
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
WO2018031425A1 (en) * 2016-08-08 2018-02-15 Glucare, Llc Pharmaceutical compositions comprising chromium and carbohydrate blockers
CN110596265A (zh) * 2019-09-03 2019-12-20 谱尼测试集团股份有限公司 一种羊乳和牛乳的鉴别方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344246A1 (en) * 1998-09-17 2000-03-23 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
CN1114618C (zh) * 2000-05-19 2003-07-16 程伶辉 三价铬复合物、其乳制品及其制造方法
CN1185258C (zh) 2000-05-19 2005-01-19 程伶辉 三价铬复合物及其应用
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
CA2471766C (en) 2001-12-28 2011-01-11 Nrl Pharma, Inc. Compositions for improving lipid metabolism
TW200605902A (en) 2004-08-05 2006-02-16 Maxluck Biotechnology Corp Composition for lowering blood lipid
CN1736478A (zh) 2004-08-17 2006-02-22 加特福生物科技股份有限公司 用以调降血脂肪的组成物
US7956031B2 (en) * 2005-05-31 2011-06-07 Naidu Lp Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
JP5414142B2 (ja) 2006-01-23 2014-02-12 雪印メグミルク株式会社 脂質代謝改善剤
JP5045879B2 (ja) 2006-06-07 2012-10-10 株式会社龍泉堂 インスリン抵抗性の改善効果、体重増加の抑制効果、及び脂肪肝の予防及び改善効果を有する混合物
US20080268069A1 (en) * 2007-04-25 2008-10-30 Ryusendo Co., Ltd. Mixture having effect of improving insulin resistance, effect of suppressing body weight gain, and effect of preventing and improving fatty liver
FI122252B (fi) * 2008-01-04 2011-10-31 Valio Oy Koostumus maksa-aineenvaihdunnan parantamiseksi ja diagnostinen menetelmä

Also Published As

Publication number Publication date
US8771752B2 (en) 2014-07-08
NL2006318C2 (en) 2011-11-08
TWI374744B (nl) 2012-10-21
TW201002332A (en) 2010-01-16
NL2006318A (en) 2011-03-28
US20100003347A1 (en) 2010-01-07
MX2009007319A (es) 2010-03-23
NL2003138C2 (en) 2011-03-07
US20120064176A1 (en) 2012-03-15
MY150701A (en) 2014-02-28

Similar Documents

Publication Publication Date Title
BRPI0920284A2 (pt) composição e método
BRPI0919575A2 (pt) método, e, composição
BRPI0912046A2 (pt) composições de hibridização e métodos
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BRPI0823277A2 (pt) Composição, e , método
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
BRPI0906973A2 (pt) Compostos e composições como inibidores de cinase.
BRPI0909707A2 (pt) Composição detergente que compreende lipase.
BRPI0914745A2 (pt) composição nutricional
BRPI0809573A2 (pt) composição, e, método
BRPI0917231A2 (pt) composição
IT1392101B1 (it) Composizione comprendente isoflavoni
AP2011005681A0 (en) Methods and formulations for treating chronic liver disease.
NL1036050C (nl) Brandvertragende en brandwerende samenstelling.
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
PL2240018T3 (pl) Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy
EP2381920A4 (en) METHOD AND COMPOSITIONS FOR TREATING P.ACNES
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
PD Change of ownership

Owner name: MAXLUCK BIOTECHNOLOGY CORP.; TW

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: NATIONAL CHUNG HSING UNIVERSITY

Effective date: 20171205

MM Lapsed because of non-payment of the annual fee

Effective date: 20230801